Soleno Therapeutics
Soleno Therapeutics Announces Initiation of Phase III Clinical Trial of DCCR in Prader-Willi Syndrome
14 mai 2018 08h00 HE | Soleno Therapeutics
REDWOOD CITY, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
Soleno Logo_2018.png
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results
02 avr. 2018 08h00 HE | Soleno Therapeutics
REDWOOD CITY, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Logo_2018.png
Soleno Therapeutics Announces Successful End-of-Phase II Meeting with FDA for DCCR in Prader-Willi Syndrome
20 févr. 2018 08h00 HE | Soleno Therapeutics
Minutes Confirm Alignment on Soleno’s Planned Phase III Clinical Trial Soleno In Process of Initiating Phase III Study REDWOOD CITY, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics,...
Soleno Logo_2018.png
Soleno Therapeutics Announces $15 Million Private Placement
12 déc. 2017 08h30 HE | Soleno Therapeutics
Financing to Support Planned Phase III Clinical Program for DCCR in Prader-Willi Syndrome REDWOOD CITY, Calif., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a...
Soleno Logo_2018.png
Soleno Therapeutics Announces Joint Venture Agreement for Development and Commercialization of CoSense Monitoring Technology
08 déc. 2017 08h00 HE | Soleno Therapeutics
REDWOOD CITY, Calif., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare...
Soleno Logo_2018.png
Soleno Therapeutics to Present at the Piper Jaffray 29th Annual Healthcare Conference
22 nov. 2017 08h00 HE | Soleno Therapeutics
REDWOOD CITY, Calif., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare...
Soleno Logo_2018.png
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results
14 nov. 2017 08h00 HE | Soleno Therapeutics
Completed Successful EMA Meeting for DCCR in Prader-Willi SyndromeContinued Preparations to Begin Phase III ProgramPresented Positive Updated Safety and Efficacy Data from Pilot Clinical Trial of DCCR...
Soleno Logo_2018.png
Soleno Therapeutics Regains Compliance with NASDAQ Listing Requirements
23 oct. 2017 08h00 HE | Soleno Therapeutics
REDWOOD CITY, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare...
Soleno Logo_2018.png
Soleno Therapeutics Receives Positive Opinion from European Orphan Committee for DCCR in Prader-Willi Syndrome
12 oct. 2017 08h00 HE | Soleno Therapeutics
REDWOOD CITY, Calif., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare...
Soleno Logo_2018.png
Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Hyperphagia in Prader-Willi Syndrome
11 oct. 2017 08h00 HE | Soleno Therapeutics
REDWOOD CITY, Calif., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare...